> IDIX – how big of a trial would they need for good power?<
I do not understand your question—IDIX has already stated that the phase-3 trial will contain one arm that tests NM83+pegifn without ribavirin.
It would make no sense to design this trial with sufficient power to show a statsig benefit for NM283+riba+pegifn vs SoC but insufficient power to show a statsig benefit of NM283+pegifn vs SoC.
Market Data 
Markets 
AI
